Current Report Filing (8-k)
June 10 2020 - 11:42AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form
8-K
Current Report Pursuant to Section 13 or
15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 6, 2020
Cannapharmarx,
Inc.
(Exact name of small business issuer as
specified in its charter)
Delaware
|
000-27055
|
24-4635140
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer ID No.)
|
3600
888-3rd Street SW
Calgary, Alberta,
Canada T2P5C5
(Address of principal executive offices)
(949) 652-6838
(Issuer’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of a Material Definitive Agreement
On June 8, 2020 we received notice from
Sunniva, Inc. of its exercise of its rights to terminate that Purchase Agreement dated June 11, 2019, as amended, wherein we had
agreed to purchase Sunniva’s wholly-owned subsidiaries Sunniva Medical Inc. and 1167025 B.C. LTD.
Item 7.01 Regulation FD Disclosure
Attached is a copy of a press release being
issued by us relating to the termination of the Purchase Agreement described in Item 1.02 above., a copy of which is attached as
Exhibit 99.1 and is hereby incorporated.
Item
9.01 Financial Statements and Exhibits.
(c) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 10, 2020
|
CANNAPHARMARX, INC.
|
|
|
|
By:
|
/s/Dominic Colvin
|
|
|
Dominic Colvin
Chief Executive Officer
|
Cannapharmarx (CE) (USOTC:CPMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cannapharmarx (CE) (USOTC:CPMD)
Historical Stock Chart
From Apr 2023 to Apr 2024